KIT and gastrointestinal stromal tumor: Since imatinib preferentially targets mutant receptors [6,9], inhibiting the IGF–IGF1R and KITLG–KIT coupled autocrine/paracrine loops may be beneficial in GIST, which are in most cases heterozygous for a given KIT mutation and continue expressing WT KIT protein [5].